NCT05653284View on ClinicalTrials.gov

A Study of AK130 in Patients With Advanced Malignant Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

December 12, 2023

Study Completion Date

May 30, 2024

Conditions

Advanced Malignant Tumors

Interventions

DRUG

AK130

IV infusion, specified dose on specified days.

Trial Locations (1)

Unknown

The Cancer Hospital Affiliated to Shandong First Medical University, Jinan

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Akeso

INDUSTRY

NCT05653284 - A Study of AK130 in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter